|
Gene: IFITM3 |
Gene summary for IFITM3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IFITM3 | Gene ID | 10410 |
Gene name | interferon induced transmembrane protein 3 | |
Gene Alias | 1-8U | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q01628 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10410 | IFITM3 | GSM4909281 | Human | Breast | IDC | 3.38e-16 | 5.31e-01 | 0.21 |
10410 | IFITM3 | GSM4909286 | Human | Breast | IDC | 1.01e-55 | -9.26e-01 | 0.1081 |
10410 | IFITM3 | GSM4909292 | Human | Breast | IDC | 1.52e-08 | -9.41e-01 | 0.1236 |
10410 | IFITM3 | GSM4909293 | Human | Breast | IDC | 9.89e-10 | -4.64e-01 | 0.1581 |
10410 | IFITM3 | GSM4909294 | Human | Breast | IDC | 1.28e-12 | -4.27e-01 | 0.2022 |
10410 | IFITM3 | GSM4909295 | Human | Breast | IDC | 7.06e-06 | -4.76e-01 | 0.0898 |
10410 | IFITM3 | GSM4909296 | Human | Breast | IDC | 3.91e-43 | 6.66e-01 | 0.1524 |
10410 | IFITM3 | GSM4909297 | Human | Breast | IDC | 3.00e-22 | 2.03e-01 | 0.1517 |
10410 | IFITM3 | GSM4909298 | Human | Breast | IDC | 3.09e-06 | -2.33e-01 | 0.1551 |
10410 | IFITM3 | GSM4909299 | Human | Breast | IDC | 7.34e-15 | 5.72e-01 | 0.035 |
10410 | IFITM3 | GSM4909300 | Human | Breast | IDC | 6.64e-09 | 5.22e-01 | 0.0334 |
10410 | IFITM3 | GSM4909301 | Human | Breast | IDC | 6.92e-32 | 6.82e-01 | 0.1577 |
10410 | IFITM3 | GSM4909304 | Human | Breast | IDC | 3.08e-54 | -8.98e-01 | 0.1636 |
10410 | IFITM3 | GSM4909306 | Human | Breast | IDC | 3.36e-09 | 4.26e-01 | 0.1564 |
10410 | IFITM3 | GSM4909307 | Human | Breast | IDC | 1.99e-35 | 6.80e-01 | 0.1569 |
10410 | IFITM3 | GSM4909308 | Human | Breast | IDC | 1.06e-21 | 5.65e-01 | 0.158 |
10410 | IFITM3 | GSM4909309 | Human | Breast | IDC | 2.12e-57 | 8.20e-01 | 0.0483 |
10410 | IFITM3 | GSM4909311 | Human | Breast | IDC | 1.46e-34 | 5.82e-02 | 0.1534 |
10410 | IFITM3 | GSM4909312 | Human | Breast | IDC | 3.05e-08 | -2.52e-01 | 0.1552 |
10410 | IFITM3 | GSM4909313 | Human | Breast | IDC | 3.39e-09 | 2.60e-01 | 0.0391 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603251 | Stomach | SIM | viral process | 41/708 | 415/18723 | 2.13e-08 | 2.33e-06 | 41 |
GO:004440351 | Stomach | SIM | biological process involved in symbiotic interaction | 30/708 | 290/18723 | 6.39e-07 | 3.87e-05 | 30 |
GO:005212651 | Stomach | SIM | movement in host environment | 19/708 | 175/18723 | 3.66e-05 | 1.05e-03 | 19 |
GO:005170151 | Stomach | SIM | biological process involved in interaction with host | 20/708 | 203/18723 | 9.18e-05 | 2.28e-03 | 20 |
GO:00444095 | Stomach | SIM | entry into host | 16/708 | 151/18723 | 1.96e-04 | 4.08e-03 | 16 |
GO:004671851 | Stomach | SIM | viral entry into host cell | 15/708 | 144/18723 | 3.70e-04 | 6.59e-03 | 15 |
GO:001907951 | Stomach | SIM | viral genome replication | 14/708 | 131/18723 | 4.43e-04 | 7.46e-03 | 14 |
GO:005079241 | Stomach | SIM | regulation of viral process | 16/708 | 164/18723 | 5.01e-04 | 8.12e-03 | 16 |
GO:00192212 | Stomach | SIM | cytokine-mediated signaling pathway | 32/708 | 472/18723 | 1.10e-03 | 1.43e-02 | 32 |
GO:190390041 | Stomach | SIM | regulation of viral life cycle | 14/708 | 148/18723 | 1.48e-03 | 1.77e-02 | 14 |
GO:00439035 | Stomach | SIM | regulation of biological process involved in symbiotic interaction | 9/708 | 72/18723 | 1.52e-03 | 1.79e-02 | 9 |
GO:00096153 | Stomach | SIM | response to virus | 26/708 | 367/18723 | 1.70e-03 | 1.96e-02 | 26 |
GO:004506921 | Stomach | SIM | regulation of viral genome replication | 9/708 | 85/18723 | 4.77e-03 | 4.12e-02 | 9 |
GO:001603230 | Thyroid | HT | viral process | 81/1272 | 415/18723 | 3.08e-18 | 2.45e-15 | 81 |
GO:001905830 | Thyroid | HT | viral life cycle | 66/1272 | 317/18723 | 1.54e-16 | 7.81e-14 | 66 |
GO:004440329 | Thyroid | HT | biological process involved in symbiotic interaction | 54/1272 | 290/18723 | 9.64e-12 | 1.73e-09 | 54 |
GO:005212630 | Thyroid | HT | movement in host environment | 36/1272 | 175/18723 | 1.73e-09 | 1.78e-07 | 36 |
GO:001907928 | Thyroid | HT | viral genome replication | 30/1272 | 131/18723 | 2.78e-09 | 2.68e-07 | 30 |
GO:005170130 | Thyroid | HT | biological process involved in interaction with host | 37/1272 | 203/18723 | 3.17e-08 | 2.29e-06 | 37 |
GO:005079227 | Thyroid | HT | regulation of viral process | 31/1272 | 164/18723 | 1.75e-07 | 9.37e-06 | 31 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFITM3 | SNV | Missense_Mutation | c.24N>A | p.Phe8Leu | p.F8L | Q01628 | protein_coding | tolerated(0.1) | benign(0.053) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
IFITM3 | SNV | Missense_Mutation | c.349N>T | p.Met117Leu | p.M117L | Q01628 | protein_coding | tolerated(0.99) | benign(0) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
IFITM3 | SNV | Missense_Mutation | c.151N>C | p.Glu51Gln | p.E51Q | Q01628 | protein_coding | deleterious(0.02) | possibly_damaging(0.511) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IFITM3 | SNV | Missense_Mutation | novel | c.212N>A | p.Cys71Tyr | p.C71Y | Q01628 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IFITM3 | SNV | Missense_Mutation | c.94C>A | p.Leu32Met | p.L32M | Q01628 | protein_coding | tolerated(0.11) | possibly_damaging(0.542) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
IFITM3 | SNV | Missense_Mutation | c.245T>C | p.Val82Ala | p.V82A | Q01628 | protein_coding | deleterious(0.01) | possibly_damaging(0.519) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
IFITM3 | insertion | Frame_Shift_Ins | novel | c.122_123insC | p.Thr42AspfsTer44 | p.T42Dfs*44 | Q01628 | protein_coding | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
IFITM3 | SNV | Missense_Mutation | novel | c.5N>G | p.Asn2Ser | p.N2S | Q01628 | protein_coding | tolerated(0.33) | benign(0.018) | TCGA-CN-A498-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |